Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy;Predictores de progresión y muerte en pacientes con infección avanzada por el VIH en la era de los tratamientos antirretrovirales de gran actividad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 3, 2004, Pages 142-149

  Reus, Sergio ^a   Portilla, Joaquín ^a   Gimeno, Adelina ^a   Sánchez Payá, José ^a   Garcia Henarejos J A ^b   Martínez Madrid, Onofre ^b   Usó, Jordi ^c   Roca, Bernardino ^c   Galindo, María José ^d   López Aldeguer, José ^e   Tasay, T ^d   Guix, J ^d   Cuadrado, J M ^f   Boix, V ^a   Merino, E ^a   Plazas, J ^a   Menasalvas, A ^g   Moreno, S ^g   Amador, C ^h   Benito, C ^h  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Allergy Section   (Spain)

^c HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^d Hospital Clínico de Valencia   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h Hospital de la Marina Baja   (Spain)

Author keywords

AIDS; Cytomegalovirus; Death; HAART; HIV; Progression

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CYTOMEGALOVIRUS; DEATH; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSPECTIVE STUDY; VIREMIA; VIRUS LOAD;

EID: 11144356110     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13058022     Document Type: Article

References (36)

1. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
2. Vlahov D, Graham N, Hoover D, Flynn C, Barlett JG, Margolick JB, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: Plasma viral load and CD4+ cell count. JAMA 1998;279:35-40.
3. Apolonio EG, Hoover DR, He Y, Saah AJ, Lyter DW, Detels R, et al. Prognostic factors in human immunodeficiency virus positive patients with a CD4+ lymphocyte count < 50/μl. J Infect Dis 1995;171:829-36.
4. Colford JM, Ngo L, Tager I. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts. Am J Epidemiol 1994;139:206-18.
5. Yarchoan R, Venzon DJ, Pluda JM, Lietzau J, Wyvill KM, Tsiatis AA, et al. CD4 counts and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991;115:184-9.
6. 6 cells/l. AIDS 2000;14:1147-53.
7. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
8. Saillour F, Bernard N, Dequae-Merchadou L, Marimoutou C, Journot V, Dabis F. Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine cohort in France, 1985 to 1994. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:171-8.
9. Studies of ocular complications of AIDS Research Group in Collaboration with de AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
10. Chevret S, Scieux C, Garrait V, Dahel L, Morinet F, Modaï J, et al. Usefulness of cytomegalovirus (CMV) antigenemia assay for predicting the ocurrence of CMV disease and death in patients with aids. Clin Infect Dis 1999;28:758-63.
11. Carton JA, Maradona JA, De Ona M, Asensi V, Melon S, Garcí a-Alcalde ML, et al. El valor pronóstico de la antigenemia y viremia por citomegalovirus para el desarrollo de enfermedad citomegálica y supervivencia de pacientes con sida. Med Clin (Barc) 1999;113:205-9.
12. Bowen EF, Sabin CA, Wilson P, Griffiths PD, Davey CC, Johnson MA, et al. Cytomegalovirus viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997;11:889-93.
13. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival. J Acquir Immune Defic Syndr 1999;22:369-78.
14. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-42.
15. Boivin G, Handfield J, Toma E, Murray G, Lalonde R, Tevere VJ, et al. Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. J Clin Microbiol 1998;36:2509-13.
16. Kravcik S, Hawley-Foss N, Víctor G, Ángel JB, Garber GE, Page S, et al. Causes of death of HIV-infected persons in Ottawa, Ontario, 1984-1995. Arch Intern Med 1997;157:2069-73.
17. Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med 1992;93:387-90.
18. Klatt EC, Nichols L, Noguchi TT. Evolving trends reavealed by autopsies of patients with the acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Ángeles, California, 1982-1993. Arch Pathol Lab Med 1994;118:884-90.
19. Sansone GR, Frengley JD. Impact of HAART on causes of death of persons with late-stage AIDS. J Urban Health 2000;77:166-75.
20. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):5-14.
21. 6/l) CD4+ T-cell count in individuals infected with HIV. AIDS 1997;11:1123-7.
22. Chene G, Easterbrook P, Juszczak E, Yu LM, Pocock SJ, Gazzard BG. Long-term survival in patients with advanced immunodeficiency. AIDS 1997;11:209-16.
23. Fiala M, Swartz J, Teklehaimanot S, Kermani V, Funnye AS, Sayre JW, et al. Zidovudine therapy, CD4+ and CD8+ counts are associated with a longer survival following AIDS onset. Lymphology 1997;30:128-36.
24. Schlumpberger JM, Wolde-Tsakid G, Yao JF, Hara J. CD8+ lymphocyte counts and the risk of death in advanced HIV infection. J Fam Pract 1994;38:33-8.
25. Spector SA, Wong R, Hsia K, IPlcher M, StemIPen MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998;101:497-502.
26. Mellors JW, Muñoz A, Giorgi JW, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
27. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996;174:704-12.
28. Yerly S, Perneger T, Hirschel T, Dubuis O, Matter L, Malinverni R, et al. A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med 1998;158:247-52.
29. Lepri AC, Katzenstein TL, Ullum H. The relative prognostic value of HIV plasma HIV RNA levels and CD4+ lymphocyte counts in advanced HIV infection. AIDS 1998;12:1639-43.
30. Hogg RS, Yip B, Chan K, Wood E, Craib K, O'Shaughnessy M, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiation triple-drug therapy. JAMA 2001;286:2568-77.
31. Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiation highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002;162:1973-80.
32. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;351:723-4.
33. Mezzaroma I, Carlesimo M, Ipnter E, Muratori DS, Di Sora F, Chiarotti F, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999;29:1423-30.
34. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997;11:621-31.
35. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor AIDS 2000 Jan 28;14:141-9.
36. Ledergerber B, Egger M, Opravil IM, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999;353:863-8.